Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience
, , , , e
19 nov 2021
INFORMAZIONI SU QUESTO ARTICOLO